Literature DB >> 6329313

Calcification inhibitors in rat and human serum and plasma.

J L Meyer, H Fleisch.   

Abstract

Rat and human serum and plasma were shown to contain considerable amounts of calcium phosphate precipitation inhibitors. Two general classes of inhibiting molecules were observed for both species: high molecular weight (approx. 30 000-200 000) and low molecular weight (less than 1000). The high molecular weight components eluted from a Bio-Gel P-200 column in two peaks, one at approx. 158 000 and a broader peak at approx. 43 000. The identity of these inhibitors is unknown at present. Low molecular weight inhibitors include magnesium, pyrophosphate, and citrate ions and at least one unidentified component that coelutes with pyrophosphate and citrate on a Bio-Gel P-4 column. Quantitatively, most of the inhibitor activity resides in the high molecular weight components and it is possible that it is this activity which is responsible for maintaining the metastability of the circulating fluids. The role of the low molecular weight components may be to regulate calcification at sites inaccessible to high molecular weight molecules.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329313     DOI: 10.1016/0304-4165(84)90284-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  The effects of serum and human albumin on calcium hydroxyapatite crystal growth.

Authors:  J Garnett; P Dieppe
Journal:  Biochem J       Date:  1990-03-15       Impact factor: 3.857

2.  Calcium phosphate saturation levels in ultrafiltered serum.

Authors:  N Eidelman; L C Chow; W E Brown
Journal:  Calcif Tissue Int       Date:  1987-02       Impact factor: 4.333

3.  Competitive adsorption of magnesium and calcium ions onto synthetic and biological apatites.

Authors:  T Aoba; E C Moreno; S Shimoda
Journal:  Calcif Tissue Int       Date:  1992-08       Impact factor: 4.333

Review 4.  Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice.

Authors:  S A Bowden; B L Foster
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 5.  Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy.

Authors:  Sasigarn A Bowden; Brian L Foster
Journal:  Drug Des Devel Ther       Date:  2018-09-24       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.